Tag Archives: Swayampakula Ramakanth

Analysts’ Top Healthcare Picks: AVEO Pharma (AVEO), NeuBase Therapeutics (NBSE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AVEO Pharma (AVEO – Research Report), NeuBase Therapeutics (NBSE – Research Report) and Allena Pharmaceuticals (ALNA – Research Report) with bullish sentiments.

X4 Pharmaceuticals (XFOR) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of $21.00. The company’s shares closed last Friday at $8.74. According to TipRanks.com, Ramakanth is a 5-star analyst

H.C. Wainwright Keeps Their Buy Rating on Harpoon Therapeutics (HARP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Harpoon Therapeutics (HARP – Research Report), with a price target of $31.00. The company’s shares closed last Friday at $15.86. According to TipRanks.com, Ramakanth is

H.C. Wainwright Sticks to Its Buy Rating for Cellectar Biosciences (CLRB)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Cellectar Biosciences (CLRB – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday at $1.55. According to TipRanks.com, Ramakanth is a 5-star analyst

H.C. Wainwright Reaffirms Their Hold Rating on Ziopharm Oncology (ZIOP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Ziopharm Oncology (ZIOP – Research Report). The company’s shares closed last Friday at $3.20. According to TipRanks.com, Ramakanth is a 5-star analyst with an average

H.C. Wainwright Sticks to Their Buy Rating for Calithera Bio (CALA)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Calithera Bio (CALA – Research Report) today and set a price target of $4.00. The company’s shares closed last Friday at $2.09, close to its 52-week low of $2.03. According